Harnessing The Power of
NK Cells to Defeat Cancer
"Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2021, moving towards broad patient access to cancer-defeating cures."
- Daniel Teper, Cytovia Therapeutics CEO
Cytovia In The News
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Antibodies
August 12th, 2020
Cytovia CEO Daniel Teper to present new EGFR Dual-Targeting CAR NK program at LifeSci Partners Summer Symposium (Wednesday, Aug 5th 9AM ET)
August 3rd, 2020